QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Volkow, N. D. Articles by Franceschi, D. Search for Related Content PubMed PubMed Citation Articles by Volkow, N. D. Articles by Franceschi, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DOPAMINE METHYLPHENIDATE

Next Article 

The Journal of Neuroscience, 2001, 21:RC121:1-5

RAPID COMMUNICATION
Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain

Nora D. Volkow^{1, 3}, Gene-Jack Wang¹, Joanna S. Fowler², Jean Logan², Madina Gerasimov², Laurence Maynard¹, Yu-Shin Ding², Samuel J. Gatley¹, Andrew Gifford¹, and Dinko Franceschi¹

Departments of ¹ Medical and ² Chemistry, Brookhaven National Laboratory, Upton, New York 11973, and ³ Department of Psychiatry, State University of New York at Stony Brook, Stony Brook, New York 11794

Methylphenidate (Ritalin) is the most commonly prescribed psychoactive drug in children for the treatment of attention deficit hyperactivity disorder (ADHD), yet the mechanisms responsible for its therapeutic effects are poorly understood. Whereas methylphenidate blocks the dopamine transporter (main mechanism for removal of extracellular dopamine), it is unclear whether at doses used therapeutically it significantly changes extracellular dopamine (DA) concentration. Here we used positron emission tomography and [¹¹C]raclopride (D2 receptor radioligand that competes with endogenous DA for binding to the receptor) to evaluate whether oral methylphenidate changes extracellular DA in the human brain in 11 healthy controls. We showed that oral methylphenidate (average dose 0.8 ± 0.11 mg/kg) significantly increased extracellular DA in brain, as evidenced by a significant reduction in B_max/K_d (measure of D2 receptor availability) in striatum (20 ± 12%; p < 0.0005). These results provide direct evidence that oral methylphenidate at doses within the therapeutic range significantly increases extracellular DA in human brain. This result coupled with recent findings of increased dopamine transporters in ADHD patients (which is expected to result in reductions in extracellular DA) provides a mechanistic framework for the therapeutic efficacy of methylphenidate. The increase in DA caused by the blockade of dopamine transporters by methylphenidate predominantly reflects an amplification of spontaneously released DA, which in turn is responsive to environmental stimulation. Because DA decreases background firing rates and increases signal-to-noise in target neurons, we postulate that the amplification of weak DA signals in subjects with ADHD by methylphenidate would enhance task-specific signaling, improving attention and decreasing distractibility. Alternatively methylphenidate-induced increases in DA, a neurotransmitter involved with motivation and reward, could enhance the salience of the task facilitating the "interest that it elicits" and thus improving performance.

Key words: attention deficit hyperactivity disorder; raclopride; Ritalin; D2 receptors; striatum; positron emission tomography; imaging; dopamine transporters

---

Copyright © Society for Neuroscience  0270-6474//$05.00/0

This article has been cited by other articles:

				N. D. Volkow, J. S. Fowler, G.-J. Wang, J. M. Swanson, and F. Telang Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications Arch Neurol, November 1, 2007; 64(11): 1575 - 1579. [Abstract] [Full Text] [PDF]

				D Devos, P Krystkowiak, F Clement, K Dujardin, O Cottencin, N Waucquier, K Ajebbar, B Thielemans, M Kroumova, A Duhamel, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease J. Neurol. Neurosurg. Psychiatry, May 1, 2007; 78(5): 470 - 475. [Abstract] [Full Text] [PDF]

				J. G. Nutt, J. H. Carter, and N. E. Carlson Effects of Methylphenidate on Response to Oral Levodopa: A Double-blind Clinical Trial Arch Neurol, March 1, 2007; 64(3): 319 - 323. [Abstract] [Full Text] [PDF]

				D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology J Psychopharmacol, January 1, 2007; 21(1): 10 - 41. [Abstract] [PDF]

				M. Ito, T. Nagai, H. Kamei, N. Nakamichi, T. Nabeshima, K. Takuma, and K. Yamada Involvement of Tissue Plasminogen Activator-Plasmin System in Depolarization-Evoked Dopamine Release in the Nucleus Accumbens of Mice Mol. Pharmacol., November 1, 2006; 70(5): 1720 - 1725. [Abstract] [Full Text] [PDF]

				M. Raiteri Functional pharmacology in human brain. Pharmacol. Rev., June 1, 2006; 58(2): 162 - 193. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help